NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRXP NRX Pharmaceuticals Inc.

Market Closed 12-20 16:00:00 EST

1.50

-0.02

-1.32%

盘后1.52

+0.02+1.33%

19:58 EST

High1.55	Low1.46	Vol380.13K
Open1.55	D1 Closing1.52	Amplitude5.92%
Mkt Cap18.09M	Tradable Cap13.87M	Total Shares12.06M
T/O571.18K	T/O Rate4.11%	Tradable Shares9.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"NRXP","market":"US","secType":"STK","nameCN":"NRX Pharmaceuticals Inc.","latestPrice":1.5,"timestamp":1734728400000,"preClose":1.52,"halted":0,"volume":380130,"hourTrading":{"tag":"盘后","latestPrice":1.52,"preClose":1.5,"latestTime":"19:58 EST","volume":3430,"amount":5196.6609,"timestamp":1734742738024},"delay":0,"floatShares":9244500,"shares":12060761,"eps":-2.124018,"marketStatus":"Market Closed","change":-0.02,"latestTime":"12-20 16:00:00 EST","open":1.55,"high":1.55,"low":1.46,"amount":571175.849439,"amplitude":0.059211,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.124018,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.52,"preHourTrading":{"tag":"盘前","latestPrice":1.5586,"preClose":1.52,"latestTime":"08:46 EST","volume":1029,"amount":1562.884096,"timestamp":1734702410985},"postHourTrading":{"tag":"盘后","latestPrice":1.52,"preClose":1.5,"latestTime":"19:58 EST","volume":3430,"amount":5196.6609,"timestamp":1734742738024},"volumeRatio":0.5702699905294167,"impliedVol":2.4463,"impliedVolPercentile":0.7103},"requestUrl":"/m/hq/s/NRXP","defaultTab":"news","newsList":[{"id":"2486077461","title":"NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2486077461","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486077461?lang=en_us&edition=fundamental","pubTime":"2024-11-26 21:03","pubTimestamp":1732626180,"startTime":"0","endTime":"0","summary":"WILMINGTON, Del., Nov. 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman, CEO and Chief Scientistwill present at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.- on Tuesday December 3, 2024 at 1:00PM Eastern Standard Time.NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7HRDUBVwDDdTEOMS.ImfaQ--~B/aD0zMzc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/5df666b7a53f66e1d5843817ccb10779","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7HRDUBVwDDdTEOMS.ImfaQ--~B/aD0zMzc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/5df666b7a53f66e1d5843817ccb10779"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-130300362.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-130300362.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","IE00B3QW5Z07.USD","BK4215","PSQ",".IXIC","SQQQ","LU2210149790.SGD","LU2210150020.SGD","BK4007","IE00BGHQF748.EUR","IE00BKPKM429.USD","MNQmain","BK4112","NRXPW","NRXP","BK4585","NQmain","IE00B64PRP62.GBP","QID","EQR","LU2095319765.USD","NBL","TQQQ","QLD","WRD","NDAQ"],"gpt_icon":1},{"id":"2486841250","title":"NRX Pharmaceuticals Price Target Maintained With a $19.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2486841250","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486841250?lang=en_us&edition=fundamental","pubTime":"2024-11-25 21:48","pubTimestamp":1732542480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 25, 2024 08:48 ET (13:48 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP"],"gpt_icon":0},{"id":"2486089006","title":"BRIEF-NRx Pharmaceuticals Announces Publication Of Paper Entitled \"Quality Assurance Of Depression Ratings In Psychiatric Clinical Trials\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2486089006","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486089006?lang=en_us&edition=fundamental","pubTime":"2024-11-25 21:22","pubTimestamp":1732540933,"startTime":"0","endTime":"0","summary":"BRIEF-NRx Pharmaceuticals Announces Publication Of Paper Entitled \"Quality Assurance Of Depression Ratings In Psychiatric Clinical Trials\"Nov 25 (Reuters) - NRX Pharmaceuticals Inc NRXP.O:NRX PHARMACE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nTUA5FRZXY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP"],"gpt_icon":0},{"id":"2486860230","title":"NRX Pharmaceuticals (Nasdaq:Nrxp) Announces Publication of Paper Entitled \"Quality Assurance of Depression Ratings in Psychiatric Clinical Trials\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2486860230","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486860230?lang=en_us&edition=fundamental","pubTime":"2024-11-25 21:03","pubTimestamp":1732539783,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nTUA5FRZXY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2486089354","title":"NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled \"Quality Assurance of Depression Ratings in Psychiatric Clinical Trials\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2486089354","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486089354?lang=en_us&edition=fundamental","pubTime":"2024-11-25 21:03","pubTimestamp":1732539780,"startTime":"0","endTime":"0","summary":"NRx-developed training and monitoring methodology in recently completed phase 2b/3 clinical trial of NRX-101 documents higher interrater reliability  on primary endpoint  than previously reported industry standards. Positive implications for conduct of future registration trials for NRX-101 and similar medications.Published in the peer reviewed American Journal of Clinical Psychopharmacology. \"The rater training and monitoring methodology achieved by NRx's research team enabled the team to identify statistically significant improvements in recovery from suicidality and reduction in akathisia  with a compact study design of 90 patients. This methodology enabled statistical significance to be achieved with fewer than 100 participants, where typically several hundred would have been required,\" said Dr. Jonathan Javitt, Chairman, CEO and Chief Scientist of NRx Pharmaceuticals and senior author of the study. \"Clinical trials in antidepressant drugs rely on close coordination of human psycho","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7HRDUBVwDDdTEOMS.ImfaQ--~B/aD0zMzc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/5df666b7a53f66e1d5843817ccb10779","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7HRDUBVwDDdTEOMS.ImfaQ--~B/aD0zMzc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/5df666b7a53f66e1d5843817ccb10779"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-130300810.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-130300810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NRXP","NDAQ",".IXIC","NRXPW"],"gpt_icon":0},{"id":"2484596704","title":"NRX Pharmaceuticals Inc (NRXP) Q3 2024 Earnings Call Highlights: Significant Reduction in ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2484596704","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484596704?lang=en_us&edition=fundamental","pubTime":"2024-11-19 15:03","pubTimestamp":1731999785,"startTime":"0","endTime":"0","summary":"Net Operating Loss Reduction: 74% reduction in net operating losses compared to Q3 2023.Net Loss: Reduced to $1.6 million in Q3 2024 from $6.1 million in Q3 2023.Research and Development Expenses: Decreased from $3.3 million in Q3 2023 to $0.6 million in Q3 2024.General and Administrative Expenses: Slight decrease from $2.5 million in Q3 2023 to $2.4 million in Q3 2024.Cash and Cash Equivalents: $1.6 million as of September 30, 2024.Additional Financing: Secured $5.4 million in tranche two of secured debt financing post-September 30, 2024.Net Loss for Nine Months: Reduced to $16.1 million in 2024 from $25.8 million in 2023.Research and Development Expenses for Nine Months: $5.2 million in 2024, down from $10.8 million in 2023.General and Administrative Expenses for Nine Months: Decreased to $10.9 million in 2024 from $12.3 million in 2023.GuruFocus has detected 2 Warning Signs with NRXP.The company is advancing its life-saving products, NRX-100 and NRX-101, for new drug application fil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nrx-pharmaceuticals-inc-nrxp-q3-070305527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NRXPW","NRXP"],"gpt_icon":0},{"id":"2484989007","title":"NRx Pharmaceuticals names Michael Abrams as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2484989007","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484989007?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:10","pubTimestamp":1731964251,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals (NRXP) announced it has appointed Michael Abrams as its permanent CFO. Abrams succeeds Interim-CFO Richard Narido, who will con...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nrx-pharmaceuticals-names-michael-abrams-as-cfo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nrx-pharmaceuticals-names-michael-abrams-as-cfo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2484989379","title":"NRX Pharmaceuticals Inc - Interim-CFO Richard Narido to Focus on Hope Therapeutics Acquisitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2484989379","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484989379?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:05","pubTimestamp":1731963904,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUA8KKN2N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2484598930","title":"NRX Pharmaceuticals (Nasdaq:Nrxp) Appoints Michael Abrams as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2484598930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484598930?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:05","pubTimestamp":1731963904,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUA8KKN2N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NDAQ","IE00BGHQF748.EUR","BK4585","NRXP","BK4007","BK4588","BK4112","IE00BKPKM429.USD","LU2095319765.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2484998954","title":"NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2484998954","media":"PR Newswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484998954?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:05","pubTimestamp":1731963900,"startTime":"0","endTime":"0","summary":"Industry veteran with extensive experience in key areas of focus. Interim-CFO Richard Narido to focus on HOPE Therapeutics acquisition opportunities. WILMINGTON,Del., Nov. 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company, today announced it has appointed Michael Abrams as its permanent Chief Financial Officer. Mr. Abrams succeedsInterim-CFO Richard Narido, who will continue to support the Company's financial function and other projects.\"We are delighted to welcome Mike to the NRx team. Mike's combination of public companyCFO experience in the biotechnology sector, together with investment banking expertise is ideally suited to NRx's needs as we aim to become a revenue generating, profitable biotechnology company,\" said Dr. JonathanJavitt, Chairman, CEO and Chief Scientist of NRx Pharmaceuticals. \"Additionally, we thank Rich for his outstanding service to the Company as ourInterim-CFO and look forward to his ongoing contributions as HOPE T","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7HRDUBVwDDdTEOMS.ImfaQ--~B/aD0zMzc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/5df666b7a53f66e1d5843817ccb10779","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7HRDUBVwDDdTEOMS.ImfaQ--~B/aD0zMzc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/5df666b7a53f66e1d5843817ccb10779"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-appoints-210500504.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-appoints-210500504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","IE00B3QW5Z07.USD","PSQ",".IXIC","SQQQ","LU2210149790.SGD","LU2210150020.SGD","BK4007","IE00BGHQF748.EUR","IE00BKPKM429.USD","MNQmain","BK4112","NRXPW","NRXP","BK4585","NQmain","IE00B64PRP62.GBP","QID","LU2095319765.USD","TQQQ","QLD","NDAQ"],"gpt_icon":1},{"id":"2483996371","title":"NRX Pharmaceuticals Inc reports results for the quarter  - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483996371","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483996371?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:09","pubTimestamp":1731679773,"startTime":"0","endTime":"0","summary":"* NRX Pharmaceuticals Inc    reported a quarterly adjusted loss of 13 cents per share for the quarter , higher than the same quarter last year, when the company reported EPS of -70 cents.  The mean ex","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NRX Pharmaceuticals Inc reports results for the quarter  - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP"],"gpt_icon":0},{"id":"2483374243","title":"Press Release: NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483374243","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483374243?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:05","pubTimestamp":1731618300,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals  Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update. -- On track to file New Drug Applications  for NRX-100 . in treating suicidal ideation in depression, including bipolar depression. bipolar depression with suicidality or akathisia by year end 2024 with. -- HOPE Therapeutics acquiring Interventional Psychiatry Clinics; key to. developing a best-in-class network of care to prevent suicide, continues. -- 74% reduction in net operating losses compared to 3rd quarter 2023 with. profitability forecast in 2025 from HOPE Therapeutics and from sales of. WILMINGTON, Del., Nov. 14, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company, today announced its financial results for the quarter and year to date ended September 30, 2024 and provided a business update.clinical trials in more than 500 patients in collaboration with leading. US and French Universities that demonstrate a highly significant.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","QID","QLD",".IXIC","SQQQ","BK4022","BK6100","BK4232","NPL.SI","IE00BKPKM429.USD","BK4588","TQQQ","NDAQ","LU2095319765.USD","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SSI","PSQ","LU2210149790.SGD","NRXP","LU2210150020.SGD","IE00B64PRP62.GBP","BK4585","MNQmain","R","BK4007"],"gpt_icon":1},{"id":"2483382093","title":"NRX Pharmaceuticals Files Registration Statement for Sale of Stock by Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2483382093","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483382093?lang=en_us&edition=fundamental","pubTime":"2024-11-15 01:46","pubTimestamp":1731606381,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals  on Thursday filed a preliminary prospectus for the sale of up to  3,304,374 of the company's common stock from time to time by some of its shareholders.The shares are issuable if the holders of the company's 6% senior secured note convert the debt into equity and exercise their warrants for stock in full.The company identified the selling shareholders as Anson Investments Master Fund and Anson East Master Fund.The company said it would not receive any proceeds from the resale of its shares.Shares of NRX Pharmaceuticals were down 6.4% in recent trading.Price: 1.17, Change: -0.08, Percent Change: -6.40","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2483027160","title":"BRIEF-NRx Pharmaceuticals Reschedules Conference Call To Discuss Third Quarter And Year To Date 2024 Financial Results To November 18, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483027160","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483027160?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:04","pubTimestamp":1731503088,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Nasdaq Inc   :   * NRX PHARMACEUTICALS, INC. (NASDAQ:NRXP) RESCHEDULES CONFERENCE CALL TO DISCUSS THIRD QUARTER AND YEAR TO DATE 2024 FINANCIAL RESULTS TO NOVEMBER 18, 2024Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TQQQ","BK4112","LU2095319765.USD","SQQQ","BK4007","BK4585","BK4588","IE00BKPKM429.USD","MNQmain","LU2210149790.SGD","IE00B64PRP62.GBP","NDAQ","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","NRXP",".IXIC","NQmain","QID","LU2210150020.SGD","PSQ","QLD"],"gpt_icon":0},{"id":"2483002106","title":"NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483002106","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483002106?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:03","pubTimestamp":1731502984,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA5MSHRT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BGHQF748.EUR","NDAQ","BK4112","LU2210150020.SGD","BK4007","BK4588","IE00BKPKM429.USD","NRXP","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2483300739","title":"NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483300739","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483300739?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:03","pubTimestamp":1731502980,"startTime":"0","endTime":"0","summary":"WILMINGTON, Del., Nov. 13, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company, today announced that it will reschedule its third quarter and year to date 2024 results conference call to Monday November 18, 2024 at 4:30pm ET, to accommodate any additional corporate news.Notice Regarding Forward-Looking StatementsThe information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as \"may,\" \"will,\" \"should,\" \"would,\" \"expect,\" \"plan,\" \"believe,\" \"intend,\" \"look forward,\" and other similar exp","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7HRDUBVwDDdTEOMS.ImfaQ--~B/aD0zMzc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/5df666b7a53f66e1d5843817ccb10779","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7HRDUBVwDDdTEOMS.ImfaQ--~B/aD0zMzc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/5df666b7a53f66e1d5843817ccb10779"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-130300959.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-130300959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","TQQQ","NRXPW","NDAQ","BK4007","BK4588","PSQ","IE00BKPKM429.USD","LU2210150020.SGD","QID","IE00B64PRP62.GBP","QLD",".IXIC","SQQQ","IE00BGHQF748.EUR","BK4112","LU2095319765.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","NRXP","NQmain","MNQmain"],"gpt_icon":1},{"id":"2483309866","title":"NRX Pharmaceuticals Inc  expected to post a loss of 64 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2483309866","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483309866?lang=en_us&edition=fundamental","pubTime":"2024-11-13 08:03","pubTimestamp":1731456195,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc  expected to post a loss of64cents a share - Earnings Preview NRX Pharmaceuticals Inc NRXP.OQ NRXP.O is expected to show no change in quarterly revenue when it reports  results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL8N3MK01C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP"],"gpt_icon":0},{"id":"2482651824","title":"NRX Pharmaceuticals Inc    expected to post a loss of 64 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482651824","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482651824?lang=en_us&edition=fundamental","pubTime":"2024-11-09 07:50","pubTimestamp":1731109837,"startTime":"0","endTime":"0","summary":"* NRX Pharmaceuticals Inc     is expected to show no change in quarterly revenue when it reports  results on November 14 for the period ending September 30 2024   *    * LSEG's mean analyst estimate f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"NRX Pharmaceuticals Inc    expected to post a loss of 64 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP"],"gpt_icon":0},{"id":"2481220901","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2481220901","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481220901?lang=en_us&edition=fundamental","pubTime":"2024-11-08 19:00","pubTimestamp":1731063600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Amer. Axle & Mnfg                                3Q      (.05)  8:00 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","OCS","COCP","CLMT","FBRX","SBS","BAX","BLMN","RBA","BNTC","ACLX","GSL","INTS","VINC","ALT","ATOS","PAA","PAGP","AMRX","XERS","NRXP","ZURA","GATO","MASS","AGO","HLLY","VRDN","AMTX","LAZR","XAIR","MSGE","NPWR","PARA","GTN","WMS","ZETA","AHR","HUMA","GCMG","AVTE","SGMT","KT","ABOS","TSBX","TSVT","ANIP","AIRS","ATSG","FLR","ATAI"],"gpt_icon":1},{"id":"2481154874","title":"NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481154874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481154874?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:06","pubTimestamp":1731013563,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUA309TQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2095319765.USD","BK4588","NRXP","BK4112","LU2210149790.SGD","BK4585","IE00B64PRP62.GBP","NDAQ","IE00B3QW5Z07.USD","BK4007","IE00BKPKM429.USD","LU2210150020.SGD","IE00BGHQF748.EUR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.salbergco.com","stockEarnings":[{"period":"1week","weight":0.25},{"period":"1month","weight":0.2397},{"period":"3month","weight":-0.0798},{"period":"6month","weight":-0.434},{"period":"1year","weight":-0.6516},{"period":"ytd","weight":-0.6739}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.17342},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.0504},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.073314},{"month":4,"riseRate":0,"avgChangeRate":-0.311577},{"month":5,"riseRate":0.666667,"avgChangeRate":0.013246},{"month":6,"riseRate":0.25,"avgChangeRate":-0.267026},{"month":7,"riseRate":0.5,"avgChangeRate":0.093346},{"month":8,"riseRate":0.25,"avgChangeRate":-0.143251},{"month":9,"riseRate":0.25,"avgChangeRate":-0.121573},{"month":10,"riseRate":0.75,"avgChangeRate":0.062005},{"month":11,"riseRate":0.5,"avgChangeRate":0.112968},{"month":12,"riseRate":0.5,"avgChangeRate":-0.007838}],"exchange":"NASDAQ","name":"NRX Pharmaceuticals Inc.","nameEN":"NRX Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NRX Pharmaceuticals Inc.,NRXP,NRX Pharmaceuticals Inc.股票,NRX Pharmaceuticals Inc.股票老虎,NRX Pharmaceuticals Inc.股票老虎国际,NRX Pharmaceuticals Inc.行情,NRX Pharmaceuticals Inc.股票行情,NRX Pharmaceuticals Inc.股价,NRX Pharmaceuticals Inc.股市,NRX Pharmaceuticals Inc.股票价格,NRX Pharmaceuticals Inc.股票交易,NRX Pharmaceuticals Inc.股票购买,NRX Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction